



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 11<sup>th</sup> December 2017**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the 13<sup>th</sup> November 2017 Medicines Group meeting were approved and will be circulated.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**4.1 Formulary Applications**

• **Brodalumab 120mg Solution for injection in pre-filled syringe (Kynthenum<sup>®</sup>) (Leo)**

Requested by the Dermatology Team for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Currently available on an Early Use Scheme (EUS) and will be reserved for patients who have failed one or more biologic therapy. This will ensure potential cost savings with the use of this drug in those patients who are intolerant of current biologic treatments for severe plaque psoriasis. It was appreciated that adding this medicine to the formulary for availability on a EUS may result in complications at a later stage if NICE approval is delayed or is not granted. Also it is not common practice to add medicines for supply on EUS on the formulary until NICE approval is granted. NICE approval is expected in December 2018. It was therefore agreed that Kynthenum<sup>®</sup> could be used within the Trust for its requested indication but it would not be added to the formulary until NICE approval is granted. It was confirmed that in the event that NICE approval is not granted that that (Leo Pharmaceuticals) would continue to provide a supply (free of charge) to patients who have already been started on it and continue to respond.

**Decision: Approved for use within the Trust but not to be added to the formulary until NICE approval granted.**

***Ex-Panel***

• **Magnesium Sulphate 185mg/3ml Nebules**

Recommended by the British Thoracic Society Guideline for Acute Severe Asthma symptoms presenting with SpO<sub>2</sub> <92%. Recommendation: Consider adding 150mg magnesium sulphate to each nebulised Salbutamol and Ipratropium in the first hour. Currently using injection 10% injection (1.5ml). Made by St. Mary's Pharmaceutical Unit in Cardiff. Use 2.5ml of the solution.

Cost impact: Nebuliser: £2.20/Nebule

Injection: £5.60/Vial

**Decision: Approved for addition to the formulary**

***NICE Approved drug applications***

• **Tofacitinib 5mg Tablets (Xeljanz<sup>®</sup>) (in line with NICE TA480 - for moderate to severe rheumatoid arthritis)**

Approved for moderate to severe Rheumatoid Arthritis by NICE in October 2017 (TA480).

**Decision: Approved for addition to the formulary**

• **Sarilumab 150mg and 200mg Solution for Injection in pre-filled syringe (Kevzara<sup>®</sup>) (in line with NICE TA485 - for moderate to severe rheumatoid arthritis)**

Approved for moderate to severe Rheumatoid Arthritis by NICE November 2017 (TA485).

**Decision: Approved for addition to the formulary**

• **Ribociclib 200mg Tablets (Kisqali<sup>®</sup>) (In line with NICE approval. NICE TA due Dec 2017)**



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Approved for Breast Cancer. NICE TA due December 2017. Approved for use within Cancer Drugs Fund.

**Decision: Approved for addition to the formulary**

- **Palbociclib 75mg, 100mg and 125mg Tablets (Ibrance<sup>®</sup>) (In line with NICE approval. NICE TA due Dec 2017)**

Approved for Breast Cancer. NICE TA due December 2017. Approved for use within Cancer Drugs Fund.

**Decision: Approved for addition to the formulary**

### **Pharmacoeconomic Board requests**

- **IVIG for Neuromyelitis Optica**

Approved by the Pharmacoeconomic Board on 30/11/17

**Decision: Noted**

- **IVIG for 2 x Grey Indications**

Two x Grey Indications:

- Autoimmune Encephalitis
- Tetanus with Lock Jaw

Approved by the Pharmacoeconomic Board in November

**Decision: Noted**

### **4.2 Trust Medicines Policy**

- **TMP: Section 8 - Administration of medicines**

Update to section 8.1 *Who can administer to specific patients* to account for the involvement of Healthcare Assistants in the administration of medicines. Administration of medicines by HCAs would be further supported by a competency framework and a risk assessment

**Decision: Approved**

- **TMP: Section 30 - Supply of over-labelled and pre-pack medicines by nurses/midwives from wards/departments**

Addition of GUM out-patient clinics as departments that can work under this policy.

Review of wording in light of adding the supply of over-labelled packs from GUM out-patient clinics.

**Decision: Approved**

### **4.3 Medicines Optimisation**

- **NHS England Consultation re. Items which should not routinely be prescribed in Primary Care**

Guidance on Items which should not routinely be prescribed in Primary Care following recent consultation.

**Decision: Noted**

- **NWL Choosing Wisely Consultation**

Email, Letter and outcome of NWL Choosing Wisely Consultation which aims to reduce the prescribing of medicines and products that can be purchased without a prescription.

**Decision: Noted**

- **Reducing medicines wastage - Utilising patient's own medicines**

Initiative being undertaken by Imperial College to reduce medicines wastage by utilising patient's own medicines.

**Decision: Noted**

- **CCP Monthly Report - November 2017**

Monthly CCP Report for November 2017



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Decision: Noted**

**4.4 NICE TA Guidance**

**NICE TA Guidance - November 2017**

**9 Appraisals were published in November 2017**

**TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer**

**Formulary status / Action**

Currently included on the formulary

**TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer**

**Formulary status / Action**

Currently included on the formulary

**TA485 - Sarilumab for moderate to severe rheumatoid arthritis**

**Formulary status / Action**

To add to formulary. Application form included in Section 4.1

**TA486 - Aflibercept for treating choroidal neovascularisation**

**Formulary status / Action**

Currently included on the formulary

**TA487 - Venetoclax for treating chronic lymphocytic leukaemia**

**Formulary status / Action**

Currently not included on formulary - To add to formulary on receipt of a completed and signed application form.

**TA488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours**

**Formulary status / Action**

Nil action as not applicable to C&W

**TA489 - Vismodegib for treating basal cell carcinoma**

**Formulary status / Action**

Nil action as not recommended

**TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy**

**Formulary status / Action**

Nil action as not relevant to C&W.

**TA491 - Ibrutinib for treating Waldenstrom's macroglobulinaemia**

**Formulary status / Action**

Currently included on the formulary

**4.5 IVIG Update**

- **IVIG requests**

**November 2017**

**CWH Site**

There were 21 IVIG issues in November 2017, with 9 new requests:

**WMUH Site**

There were 18 IVIG issues in November 2017, with 6 new requests:

**Decision: Approved**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**4.6 Items for noting**

• **Trust Medicines Group Meeting dates for 2018**

Dates for TMG meetings 2018

**Decision: Noted**

• **MHRA Drug Safety Update - November 2017**

MHRA update for November 2017

**Decision: Noted**

**4.7 Meeting minutes for noting**

• **Antimicrobial Stewardship Group Meeting - September 2017**

Minutes from Antimicrobial Stewardship Group Meeting - September 2017

**Decision: Noted**

• **Medication Safety Group Meeting - October 2017**

Minutes from Medication Safety Group Meeting - October 2017

**Decision: Noted**

• **Clinical Chemotherapy Service Group Meeting - September 2017**

Minutes from Clinical Chemotherapy Service Group Meeting – September 2017

**Decision: Noted**

**4.8 Additional papers to go to Trust patient Safety Group**

Nil

**5. Any other business**

Nil

**6. Date of next meeting**

**Date: Monday 12<sup>th</sup> February 2018**

**Time: 8am-9am**

**Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)**

**Closing date: 19<sup>th</sup> January 2017**